Last reviewed 2026-04-23 · How we verify

Pro-netupitant/Palonosetron

Pro-netupitant is a substance P/neurokinin 1 (NK1) receptor antagonist, while palonosetron is a 5-HT3 receptor antagonist.

Pro-netupitant is a substance P/neurokinin 1 (NK1) receptor antagonist, while palonosetron is a 5-HT3 receptor antagonist. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).

At a glance

Mechanism of action

Pro-netupitant works by blocking the action of substance P/neurokinin 1 (NK1) receptors, which are involved in nausea and vomiting. Palonosetron, on the other hand, blocks the action of 5-HT3 receptors, which are also involved in nausea and vomiting. By blocking these receptors, pro-netupitant/palonosetron combination helps to prevent nausea and vomiting caused by chemotherapy.

Approved indications

• Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)

Common side effects

• Headache
• Nausea
• Vomiting
• Diarrhea
• Fatigue

Key clinical trials

• A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer (PHASE3)
• A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Pro-netupitant/Palonosetron CI brief — competitive landscape report
• Pro-netupitant/Palonosetron updates RSS · CI watch RSS
• Helsinn Healthcare SA portfolio CI